Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy.

摘要: Objective: Neoadjuvant concurrent chemoradiotherapy (CCRT) is an increasingly common therapeutic strategy for locally advanced rectal cancer, but stratification of risk and final outcomes remain a major challenge. Transcobalamin 1 (TCN1), vitamin B12 (cobalamin)-binding protein, regulates cobalamin homeostasis. High expression TCN1 have been reported in neoplasms such as breast cancer hepatocellular carcinoma. However, little known about the relevance to receiving CCRT. This study examined predictive prognostic impact patients with following neoadjuvant Methods: Through data mining from published transcriptome cancers (GSE35452), we identified upregulation gene most significantly predicted poor response CCRT among ion transport-related genes (GO:0006811). We evaluated immunohistochemistry performed H-score analysis on endoscopic biopsy specimens 172 followed by curative surgery. Expression levels were further correlated clinicopathologic features, response, tumor regression grade (TRG) survivals including metastasis-free survival (MeFS), disease-specific (DSS) recurrent-free (LRFS). Results: overexpression was related post-treatment (T3, T4; p<0.001) nodal status (N1, N2; p<0.001), vascular invasion (p=0.003) inferior (p < 0.001). In analyses, associated shorter DSS (p<0.0001), MeFS (p=0.0002) LRFS (p=0.0001). Furthermore, it remained independent prognosticator worse (p=0.002, hazard ratio=3.344), (p=0.021, ratio=3.015) (p=0.037, ratio=3.037) multivariate comparison. Conclusion: Overexpression adverse CCRT, justifying potential value